Four-year survival outcomes with dostarlimab plus chemotherapy in dMMR/MSI-H primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial.
Saved in:
| Title: | Four-year survival outcomes with dostarlimab plus chemotherapy in dMMR/MSI-H primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial. |
|---|---|
| Authors: | Powell, Matthew1 (AUTHOR), Zub, Oleksandr2 (AUTHOR), Gilbert, Lucy3 (AUTHOR), Koliadi, Anthoula4 (AUTHOR), Willmott, Lyndsay5 (AUTHOR), Black, Destin6 (AUTHOR), Ronzino, Graziana7 (AUTHOR), Sharma, Sudarshan8 (AUTHOR), Gropp-Meier, Martina9 (AUTHOR), Landrum, Lisa10 (AUTHOR), Thijs, Anna11 (AUTHOR), Lokich, Elizabeth12 (AUTHOR), Gold, Michael13 (AUTHOR), Gill, Sarah14 (AUTHOR), McCourt, Carolyn1 (AUTHOR), Cass, Ilana15 (AUTHOR), Grimshaw, Matthew16 (AUTHOR), Austin, Laura17 (AUTHOR), Edelson, Mitchell18 (AUTHOR), Nøttrup, Trine19 (AUTHOR) |
| Source: | Gynecologic Oncology. May2026:Supplement, Vol. 208, pS65-S66. 2p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
